Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7304-7310

  Micha, Dimitra ^a   Cummings, Jeff ^a   Shoemaker, Alex ^b   Elmore, Steven ^b   Foster, Kelly ^b   Greaves, Martin ^a   Ward, Tim ^a   Rosenberg, Saul ^b   Dive, Caroline ^a   Simpson, Kathryn ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE 3; CYTOKERATIN 18; ABT-737; ANTINEOPLASTIC AGENT; BH 3; BIOMIMETIC MATERIAL; BIPHENYL DERIVATIVE; BUTYLCRESOL; DRUG DERIVATIVE; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CELL DEATH; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMIMETIC MATERIALS; BIPHENYL COMPOUNDS; BUTYLATED HYDROXYTOLUENE; CASPASE 3; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-18; LUNG NEOPLASMS; MICE; NITROPHENOLS; PIPERAZINES; SMALL CELL LUNG CARCINOMA; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149340163     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0111     Document Type: Article

References (36)

1. Workman P. Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction. Expert Rev Anticancer Ther 2002;2:611-4.
2. Taylor K, Micha D, Ranson M, Dive C. Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opin Investig Drugs 2006;15:669-90.
3. Cummings J, Ranson M, Butt F, Moore D, Dive C. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol 2007;60:921-4.
4. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. Biomarker method validation in anticancer drug development. Br J Pharmacol 2007;153:646-56.
5. Linder S. Cytokeratin markers come of age. Tumour Biol 2007;28:189-95.
6. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
7. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
8. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004;1644:83-94.
9. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-91.
10. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-88.
11. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67:1176-83.
12. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99.
13. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4:1681-89; discussion 90.
14. Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007;4:e294.
15. Kuroda J, Kimura S, Strasser A, et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007;14:1667-77.
16. Shoemaker AR, Oleksijew A, Bauch J, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006;66:8731-9.
17. Trudel S, Stewart AK, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007;13:621-9.
18. Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007;21:1549-60.
19. Kohl TM, Hellinger C, Ahmed F, et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007;21:1763-72.
20. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-39.
21. Lane EB, Alexander CM. Use of keratin antibodies in tumor diagnosis. Semin Cancer Biol 1990;1:165-79.
22. Hatzfeld M, Franke WW. Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides. J Cell Biol 1985;101:1826-41.
23. Steinert PM, Roop DR. Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 1988;57:593-625.
24. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-6.
25. Biven K, Erdal H, Hagg M, et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003;8:263-8.
26. Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999;187:567-72.
27. Schutte B, Henfling M, Kolgen W, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004;297:11-26.
28. Demiray M, Ulukaya EE, Arslan M, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 2006;24:669-76.
29. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007;56:399-404.
30. Cummings J, Ward TH, LaCasse E, et al. Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG3 5156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 2005;92:532-8.
31. Hagg-Olofsson M, Cummings J, Fayad W, et al. Determining tumour cell death in the plasma of xenograft-bearing rodents, Cancer Biomarkers. In press 2008.
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
33. Olofsson MH, Ueno T, Pan Y, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 2007;13:3198-206.
34. Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 2003;39:769-74.
35. Larson CJ, Moreno JG, Pienta KJ, et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004;62:46-53.
36. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007;14:943-51.